Shanghai Tasly Pharmaceutical Co., Ltd. announced that it expects to receive CNY 74.3631 million in funding from Tasly Pharmaceutical Group Co., Ltd., Tianjin Tasly Enterprise Management Co., Ltd.
April 19, 2018
Share
Shanghai Tasly Pharmaceutical Co., Ltd. announced that it will receive CNY 74,363,100 in an equity round of funding on April 20, 2018. The transaction will involve participation from existing investors Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535) for CNY 55,000,000, Tianjin Tasly Enterprise Management Co., Ltd. for CNY 19,363,100 of which CNY 35,000,000 and CNY 1,842,100 respectively will be added to the registered capital of the company and remaining proceeds will go towards the capital reserve of the company. Post the closing of the transaction, the registered capital of the company will increase from CNY 953,861,420 to CNY 990,703,520 and the investors will continue to retain their existing stakes in the company. The company reported total assets of CNY 718,403,997.25, total liabilities of CNY 324,242,492.34, net assets of CNY 394,161,504.91, operating revenue of CNY 100,268,974.51, and net profit of CNY -71,176,693.13 for the year ended December 31, 2017.
Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.
Shanghai Tasly Pharmaceutical Co., Ltd. announced that it expects to receive CNY 74.3631 million in funding from Tasly Pharmaceutical Group Co., Ltd., Tianjin Tasly Enterprise Management Co., Ltd.